Is BMEA or BOLT more undervalued in 2026?

CirclFi compares Biomea Fusion, Inc. (BMEA) and Bolt Biotherapeutics, Inc. (BOLT) using 13 institutional-grade valuation models. BMEA has a Quality of Company score of 4.0/10 while BOLT scores 5.9/10.

Which is a better buy — BMEA or BOLT?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do BMEA and BOLT valuations compare?

BMEA at $1.38 and BOLT at $5.30 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

BMEA vs BOLT Valuation Comparison 2026 — Intrinsic Value Analysis

BMEA

Biotechnology

Biomea Fusion, Inc.

Quality

4.0

out of 10

Value Trap

SAFE

Price

$1.38

Last close

Models

9/13

Active

BOLT

Biotechnology

Bolt Biotherapeutics, Inc.

Quality

5.9

out of 10

Value Trap

LOW

Price

$5.30

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	BMEA Fair Value	BMEA Upside	BOLT Fair Value	BOLT Upside
Bayesian DCF	Intrinsic	$0.51	-63.2%	$0.54	-88.5%
Earnings Power Value	Intrinsic	$1.22	-10.6%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.72	-48.1%	$17.21	+224.6%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for BMEA vs BOLT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BMEA vs BOLT — Which Stock Is More Undervalued?

BOLT scores higher with a 5.9/10 quality rating vs BMEA's 4.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Biomea Fusion, Inc. (BMEA) and Bolt Biotherapeutics, Inc. (BOLT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BMEA currently trades at $1.38 with a QOC of 4.0/10, while BOLT trades at $5.30 with a QOC of 5.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).